Lucentis 10 mg/ml. 0.23 ml. (2 needles)

Lucentis 10 mg/ml. 0.23 ml. (1 needle)

$0.00

Manufactured in: Europe

Lucentis 10 mg/mL is a prescription medication for intravitreal injection to treat various eye conditions, with dos dosing tailored to individual needs.

Out of stock

SKU: MED6055 Category:

Description

Lucentis 10 mg/ml. – Drug Description

Lucentis is a prescription medication that contains the active ingredient ranibizumab. It is available in a concentration of 10 mg/ml. and is supplied in a 0.23 ml. vial with 1 needle for injection. Lucentis is used to treat various eye conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).

Indications and Usage

Lucentis is indicated for the treatment of the following conditions:

  • Wet age-related macular degeneration (AMD): Lucentis is used to treat neovascular (wet) AMD, which is characterized by abnormal blood vessel growth under the retina.
  • Diabetic macular edema (DME): Lucentis is indicated for the treatment of DME, which is swelling of the macula in patients with diabetic retinopathy.
  • Macular edema following retinal vein occlusion (RVO): Lucentis is used to treat macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Dosage and Administration

Lucentis is administered as an intravitreal injection into the affected eye by a healthcare professional. The recommended dosage is 0.5 mg. (0.05 ml) of Lucentis per injection. The injection may be repeated monthly or as needed based on the patient’s response to treatment and disease progression.

Contraindications

Lucentis is contraindicated in patients with known hypersensitivity to ranibizumab or any of the other ingredients in the formulation. It should not be used in patients with ocular or periocular infections.

Warnings and Precautions

Before using Lucentis, healthcare providers should consider the following warnings and precautions:

  • Endophthalmitis: Intravitreal injections, including Lucentis, have been associated with the risk of developing endophthalmitis, which is a serious eye infection.
  • Increased intraocular pressure (IOP): Lucentis may cause an increase in intraocular pressure, which should be monitored during treatment.
  • Retinal detachment: Patients receiving Lucentis injections are at an increased risk of retinal detachment, which may require surgical intervention.

Adverse Reactions

The most common adverse reactions associated with Lucentis include:

  • Eye pain
  • Increased intraocular pressure
  • Floaters in the eye
  • Conjunctival hemorrhage
  • Eye irritation

Patients should report any new or worsening symptoms to their healthcare provider promptly.

Drug Interactions

Lucentis has no known drug interactions, but patients should inform their healthcare provider about all medications, vitamins, and supplements they are taking before starting treatment with Lucentis.

Storage and Handling

Lucentis should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. Do not freeze Lucentis, and do not use the medication if it has been frozen.

Conclusion

Lucentis is a valuable treatment option for patients with various eye conditions, including wet AMD, DME, and macular edema following RVO. By following the prescribed dosage and administration guidelines, patients can benefit from the therapeutic effects of Lucentis while minimizing the risk of adverse reactions. It is important for patients to communicate openly with their healthcare provider about any concerns or side effects experienced during treatment with Lucentis.

Related products